Although the significance of these two cytokines in MuSK-related MG is not well known, treatment methods based on IL-6 and IL-12 inhibition might presumably prove beneficial for MuSK antibody-positive MG patients, as well. This evidence concerns the gene IL6 and myasthenia gravis.